Crohn’s & Colitis Congress™

Sessions Speakers Exhibitors Floor Plan Buzz

P214 - TRENDS IN THE INCIDENCE AND OUTCOMES OF CHOLANGITIS IN HOSPITALIZED PATIENTS OF ULCERATIVE COLITIS: NATIONWIDE ANALYSIS 2002-2014 (Room Poster Hall)

Introduction: Most of the cholangitis cases in inflammatory bowel disease (IBD) are attributable to primary sclerosing cholangitis (PSC) and less commonly to bacterial cholangitis and cholangitis with choledocholithiasis. We aimed to assess the characteristics of UC patients with cholangitis and to compare their prognosis with UC patients without cholangitis. Methods: We analyzed the National Inpatient Sample (NIS) database for all subjects with discharge diagnosis of UC with or without cholangitis as primary or secondary diagnosis via ICD 9 codes during the period from 2002-2014. All analyses were performed with the use of SAS (version 9.4) Results: From 2002-2014, there were total 24647 discharges of UC with Cholangitis, constituting 2.1% discharges of all patients of UC. UC patients with cholangitis were younger and aged below 50 (2.8% Vs 1.6 %, P=<0.001), with male predominance (66.4% Vs 45.4%, P=<0.001), more African Americans (15% Vs 8.7%, P=<0.001), with charlson comorbidity index of 2 or above (34.4% Vs 22%, P=<0.001), admitted non-electively (82.1% Vs 78.5%, P=<0.001), more odds of discharge to short term hospitals (4.5% Vs 2.3%, P=<0.001), more odd of admission to urban teaching hospitals (72.9% Vs 51.5%, P=<0.001) and with large bed size (73% Vs 63.5%, P=<0.001), more privately insured (57.4% Vs 43.2%, P=<0.001). The trend analysis showed slow and consistent rise in incidence of cholangitis in UC from 2002 (1.94%) to 2014 (2.57%). The mortality didn’t change significantly in this cohort from 2002 (1.9%) to 2014 (2.2%). Conclusions: Young African American Males with UC are more at risk of cholangitis. Patients with UC and cholangitis are treated more intensively. In patients with UC and cholangitis, malignancy is an independent predictor of mortality. The threshold of screening for malignancy should be low in this cohort for timely diagnosis and treatment with aim of reducing mortality.